NATCO Pharma Limited share price
NSE: NATCOPHARM · ISIN INE987B01026
Key numbers
- Market cap
- ₹ 15,307 Cr
- Current price
- ₹ 839.30
- 52-week high / low
- ₹ 1,227 / 789
- Stock P/E
- 13.1
- Book value
- ₹ 514.9
- Dividend yield
- 0.71%
- ROCE
- 17.0%
- ROE
- 16.9%
- Debt to equity
- 0.08
- Sales growth (3 yrs)
- 14.5%
- Profit growth (3 yrs)
- 25.6%
- 1-year return
- -1.7%
About NATCO Pharma Limited
NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Agrochemicals. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company offers neurology, cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company provides agro chemicals and biological pest management solutions for management of insects, fungicides, herbicides, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is…
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 1,329 | 1,363 | 647 | 739 | 735 |
| Operating profit | 571 | 579 | 159 | 128 | 187 |
| Net profit | 481 | 518 | 152 | 268 | 207 |
| EPS (₹) | 26.84 | 28.94 | 8.46 | 14.96 | 11.53 |
Investor presentation summary (2026-08-19)
AI summary of the presentation · tone: Positive · source document
Key numbers
- EBITDA margin* (%) 30.9% 45.5% 25.1% 53.3% 39.6%
- PAT margin (%) 26.0% 34.5% 32.9% 39.4% 32.4%
Guidance & outlook
- including the terms “believes”, “estimates”, “anticipates”, “projects”, “expects”, “intends”, “may”, “will”, “seeks” or “should” or, in each case, their negative or other variations or comparable terminology, or
- FY26 Revenue: INR 2,347 Mn
Growth & demand
- Key Para IV products in the pipeline (Filing on NCE-1) dateKey Solo FTFs (Para IV) in the pipeline
- Launched the most affordable GLP-1 in the market in the vial form. Also, launched
Margins & costs
- Revenue (INR Mn) EBITDA (INR Mn) PAT (INR Mn)
- integration & cost optimization.
Capex & expansion
- to successfully implement our strategy (ii) our growth and expansion plans (iii) changes in regulatory norms applicable to the Company (iv) technological changes (v) investment and business income (vi)
- 2 API and 2 FDF plants are USFDA approved, other
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.